



# BETA DRUGS LIMITED

**BDL/PKL/SEC/2025**  
**13<sup>th</sup> November, 2025**

To  
The Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## **SYMBOL-BETA**

**Sub.: Intimation of receipt of the In-principle approval from National Stock Exchange of India Limited for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board (NSE).**

**Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform that **BETA DRUGS LIMITED** ("the Company") has received the In-principle approval for migration of trading in equity share of the company from SME platform (Emerge) to Main Board (NSE) vide letter Ref: NSE/LIST/274, dated November 12, 2025 from National Stock Exchange of India Limited.

Please find enclosed herewith a copy of the In-principle Approval of the National Stock Exchange of India Limited.

Kindly take the above information on record.

Thanking You  
Your's faithfully  
For Beta Drugs Ltd.

Beta Drugs Limited  
  
Company Secretary  
ACS - 24684

Rajni Brar  
Company Secretary

**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)

Ref: NSE/LIST/274

November 12, 2025

The Company Secretary  
Beta Drugs Limited

Dear Sir/Madam,

**Re: In-principle approval for migration of trading in the equity shares of the Company from SME Platform (EMERGE) to Main Board.**

We are in receipt of your application regarding in-principle approval for migration of trading in the 10094553 equity shares of Rs. 10/-each of the company from SME Platform (EMERGE) to Main Board in terms of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018.

In this regard, the Exchange is pleased to grant in-principle approval for proposed migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board.

Kindly note that the Exchange will issue final approval for migration of trading in the equity shares of the company from SME Platform (EMERGE) to Main Board on submission of listing application including equity listing agreement.

“Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any.”

This In-principle approval is valid for a period of 45 days from the date of issuance of this letter.

Yours faithfully,  
For National Stock Exchange of India Limited

Ankita Gupta  
Manager

This Document is Digitally Signed



Signed by: Ankita Gupta  
Date: Wed, Nov 12, 2025 17:35:48 IST  
Location: NSE